About this episode

The episode features an interview with Dr. Marija Balic discussing how whole exome sequencing of ctDNA can inform therapy options for patients with triple negative early breast cancer post-neoadjuvant treatment.

Whole Exome Sequencing of ctDNA Informs Post-Neoadjuvant Therapy Options for Patients with Triple Negative Early Breast Cancer An interview with: Marija Balic MD PhD, Chief of Medical Breast Oncology, NSABP Foundation, Inc.; UPMC Hillman Cancer Center; University of Pittsburgh School of Medicine, Pittsburgh, PA SAN DIEGO, USA—In patients with triple negative breast cancer whole exome testing for ctDNA positivity after neoadjuvant therapy (before surgery) was found to be highly predictive of early relapse. This was in a study from Pittsburgh in the USA, reported to the 2026 Annual Meeting of the American Association for Cancer Research. First author Marija Balic MD PhD, Chief of Medical Breast Oncology at the NSABP Foundation, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, in Pittsburgh, explained to our reporter Peter Goodwin how this could predict treatment resistance and greatly help the choice of further therapy: AUDIO JOURNAL OF ONCOLOGY: Marija Balic MD PhD IN: [GOODWIN] “I am here at the American …. OUT:…..of Oncology, I’m Peter Goodwin 10:30 secs AACR 2026 ABSTRACT: CT013 – Whole-exome sequencing tumor-informed circulating tumor DNA…

Explore listener stats, chart rankings, contacts and more on the Audio Journal of Oncology Podcast podcast page.